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SUMMARY
A 46-year-old woman with a history of dasatinib-
resistant chronic myeloid leukaemia, clonal evolution and
monosomy 7 underwent reduced intensity conditioned in
vivo T-cell-depleted allogeneic haematopoietic stem cell
transplantation (HSCT) from a matched unrelated donor.
Following the transplantation, she developed recurrent
cutaneous graft versus host disease (GvHD), which
required treatment with systemic immunosuppression and
electrocorporeal photophoresis. Concurrently, she
developed a lichenoid rash with granulomatous features
suggestive of cutaneous sarcoidosis. Additional treatment
with hydroxychloroquine was initially successful, but
2 months later, she developed erythroderma with
palpable lymphadenopathy. Repeated histological
analysis established a diagnosis of folliculotropic mycosis
fungoides stage IVA2, and the malignant clone was
conﬁrmed to be of donor origin. A positive response to
brentuximab has been shown. This is the ﬁrst reported
case of primary mycosis fungoides after matched
unrelated donor HSCT, and in a patient still undergoing
treatment for GvHD.
BACKGROUND
Allogeneic haematopoietic stem cell transplantation
(HSCT) was the standard of care for patients for
chronic myeloid leukaemia (CML) until the advent
of tyrosine kinase inhibition. Since then, HSCT has
been reserved for those with resistance to tyrosine
kinase inhibition or advanced disease.1 HSCT is
associated with an increased risk of secondary
malignancies, the most common of which are post-
transplant lymphoproliferative disorders (PTLD).
Long-term immunosuppression with calcineurin
inhibitors such as ciclosporin and tacrolimus is
thought to contribute to this increased risk, as
described in cardiac transplantation where pro-
found immunosuppression is required within the
ﬁrst year.2 PTLD after HSCT is usually comprised
of Epstein Barr Virus (EBV)-associated donor-
derived B-cell lymphomas, which typically arise in
the ﬁrst 6 months post-HSCT.3 In contrast, T-cell
lymphomas are rarer and are not EBV associated.
While up to 15% of PTLD after solid organ trans-
plantation are T-cell derived, there are only anec-
dotal reports of T-cell lymphoma following HSCT.4–
9 Here, we report what is to the best of our knowl-
edge, the ﬁrst case of mycosis fungoides following
HSCT from a HLA-matched unrelated donor.
Despite its rarity, this case exempliﬁes the need for a
high index of suspicion in patients with indistinct
clinical pathology who have risk factors for second-
ary malignancies, particularly prolonged and pro-
found immunosuppression. Serial histopathological,
molecular analyses and the expertise of three disci-
plines were required to reach a diagnosis. A positive
response to brentuximab has been shown.
CASE PRESENTATION
A 46-year-old woman with a history of CML diag-
nosed in the ﬁrst chronic phase demonstrated dasati-
nib resistance associated with clonal evolution
and monosomy 7. Consequently, she underwent
a reduced intensity conditioned (ﬂudarabine
30 mg/m2 for 5 days and melphalan 140 mg/m2 for
1 day) in vivo T-cell-depleted (alemtuzumab total
dose—50 mg) unrelated donor allogeneic haemato-
poietic stem cell transplant (HSCT) in August 2010.
Her donor was a man and matched for the human
leucocyte antigens (HLA) A, B, C, DRB and DRQ.
Graft versus host disease (GvHD) prophylaxis with
ciclosporin was initiated 2 days pre-transplant.
At day 100 post-transplant, examination of bone
marrow revealed complete donor chimerism and a
morphological remission. BCR-ABL transcripts have
remained undetectable since so that it is likely a
cure was achieved.
In October 2010, the patient developed biopsy-
proven acute cutaneous GvHD (ﬁgure 1A). This
was treated with oral prednisolone and continued
ciclosporin, but she developed recurrent severe
cutaneous chronic GvHD and was unable to with-
draw from oral immunosuppression. Thus, extra-
corporeal photopheresis (ECP) was started in
March 2012, and over the next 20 months,
immunosuppression was tapered to 10 mg prednis-
olone daily and 150 mg ciclosporin daily.
In November 2013, the patient developed a new
pruritic and lichenoid rash atypical of the preceding
GvHD (ﬁgure 1B) consistent with cutaneous sarcoid-
osis. This rash initially responded to treatment with
hydroxychloroquine in conjunction with continued
immunosuppression and ECP, but in July 2014, the
patient developed a worsening of the rash with
intense pruritus and erythroderma. A trial of drug
withdrawals did not improve the eruption, which
continued to evolve. By November 2014, it was
accompanied by palpable cervical lymphadenopathy.
INVESTIGATIONS
Investigations were carried out in November 2014.
Kinsella FAM, et al. BMJ Case Rep 2017. doi:10.1136/bcr-2016-216331 1
Findings that shed new light on the possible pathogenesis of a disease or an adverse effect
ﬂuorodeoxyglucose positron emission tomograghy (FDG-PET)
imaging revealed lymphadenopathy above and below the dia-
phragm. The largest lymph nodes measured up to 3.2×1.7 cm
were located in the pre-pectoral and axillary regions, and were
the most avid (standardised uptake value (SUV) max 5.8).
Histological examination of the skin at this point revealed a loss
of features characteristic for GvHD or granulomatous inﬁltrate,
but displayed an atypical T-lymphocytic inﬁltrate (ﬁgure 1C, D)
with folliculotropism. Histological analysis of an enlarged cervical
lymph node revealed complete effacement of nodal architecture
by small atypical lymphocytes with marked nuclear irregularity
and pale cytoplasm (ﬁgure 1E, F). The T-cell inﬁltrate displayed
an inverted CD4:CD8 ratio of 1:2, and immunohistochemical
studies showed that the inﬁltrate expressed CD3 (ﬁgure 1G),
CD4, CD5 and CD43. Thirty per cent had downregulated CD7
surface expression, while 30% expressed Ki67 (ﬁgure 1H), and
the inﬁltrate was Epstein Barr virus encoded RNAs (EBER)
negative.
Clonality studies conﬁrmed the presence of an identical
clonal TCRβ rearrangement in skin and lymph node biopsies,
thus conﬁrming a diagnosis of cutaneous T-cell lymphoma
(CTCL) (ﬁgure 2A, B), stage IVA2 (T4 N3 M0 B0) folliculotro-
pic mycosis fungoides (T4, N3, M0, B0) (ﬁgure 2C) and stage
N3 according to the EORTC WHO classiﬁcation.10
Figure 1 Skin biopsy histology. (A)
October 2010. Skin biopsy of the initial
diagnostic rash of acute GvHD (×10).
(B) November 2013. Skin biopsy of the
progressive rash involving epidermis,
dermis and subcutis with dense
per-vascular lymphocytic inﬁltrate (×4).
(C) November 2014. Skin biopsy of the
erythrodermic rash revealed extensive
CD3 expression denoting a
T-lymphocytic inﬁltrate (×20). (D) The
skin inﬁltrate from was made up of
atypical T-cells with nuclear irregularity
and pale cytoplasm (×600). (E).
Excised peripheral draining lymph node
had a disrupted follicular architecture
(×20). (F) The follicular architecture
was effaced by atypical lymphocytes
similar to those found in the skin
(×200). (G). The atypical lymphocytes
effacing the lymph node follicular
region were CD3+ T-cells (×40). (H)
Approximately 30% of the lymph node
T-cell inﬁltrates expressed Ki-67 (×40).
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Microsatellite and XY-FISH studies conﬁrmed that the malig-
nant inﬁltrate was of donor origin.
TREATMENT
Please see the ‘Outcome and follow-up’ section.
OUTCOME AND FOLLOW-UP
The patient remained erythematous (mSWAT score of 200) and
failed to respond to 4 cycles of gemcitabine monotherapy and
taper of immunosuppression. Further FDG-PET imaging
revealed an increase in metabolic activity of affected nodes (axil-
lary lymph node SUV max 6.9), along with new splenomegaly
(24 cm) exhibiting increased diffuse activity. While still receiving
ECP for GvHD, she initiated brentuximab (1.8 mg/kg dose) with
the aim of disease control. After 3 cycles, she experienced signiﬁ-
cant diarrhoea and grade 1 peripheral neuropathy, and the dose
of brentuximab was reduced to 1.2 mg/kg. She has subsequently
received a further four cycles with no further detrimental effects,
Figure 2 (A) TCRβ gene clonality. Results from the skin and lymph node were obtained 4 years post-RIC HSCT. Weak clonality of the TCRβc region
* and a restricted repertoire of the TCRβb region were found in skin and lymph node. (B) TCRγ gene clonality. The TCRγ gene locus was polyclonal.
(C) Clinical photography taken of areas of the skin affected by erythroderma at the time of diagnosis of CTCL (4 years post-HSCT), prior to
treatment, and (D) following the failure of gemcitabine mono therapy.
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and has experienced a signiﬁcant reduction in lymphadenopathy
and B symptoms. Her quality of life has improved, and her
Eastern Cooperative Oncology Group (ECOG) has dropped
from 3 to 1. However, despite these improvements, she remains
pruritic with an mSWATscore of 100 (ﬁgure 2D).
DISCUSSION
We report the ﬁrst case of erythrodermic mycosis fungoides fol-
lowing allogeneic HSCT to derive from a matched unrelated
donor. ‘Transmission’ of donor-derived T-cell lymphoma and
leukaemia via HSCT has been reported previously.4 9 11 In these
instances, the sibling donors developed identical disease, but
they demonstrated subclinical pathology at the time of diagnosis
in the HSCT recipients. While these cases support the theory of
a ‘malignant stem cell’ transferred within the allograft,12 tem-
poral dissociations highlight the multifactorial aetiology of
donor-derived secondary malignancies post-HSCT. Such risk
factors are diverse but include donor genetics, total body irradi-
ation, chronic GvHD and long-term immunosuppression.3 In
this case, the patient had a higher risk of secondary malignancy
by virtue of recurrent GvHD requiring prolonged and profound
immunosuppression, which may have permitted immune
evasion of an evolving malignant clone. With this in mind, it is
interesting to note that the other two patients reported with
primary CTCL post sibling donor allogeneic HSCTalso received
at least 1 year of oral immunosuppression with calcineurin inhi-
bitors for GvHD exhibiting cutaneous manifestations.5 9
Here, information related to the anonymous unrelated donor
was understandably limited, but the relevant donor registry was
informed of the potential risk of malignancy for the donor.
It is known that CTCL may present indolently,11 but the
heterogenous presentation of this case, along with the require-
ment for ongoing GvHD therapy, complicated diagnosis. It may
be postulated that ECP, originally developed for the treatment
of erythrodermic CTCL,13 inhibited an earlier fulminant
clinico-pathological presentation. Indeed, a review of histo-
logical examinations undertaken at the time of presumed cuta-
neous sarcoid suggested that in retrospect, the ‘cytologically
bland’ lymphocytic inﬁltrates did have a similar folliculocentric
pattern of inﬁltration as the later folliculotropic mycosis fun-
goides, and that the granulomatous response may have been due
to a rupture reaction.
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Learning points
▸ Survivorship following haematopoietic stem cell
transplantation (HSCT) is of increasing importance as the
safety of the procedures improves. Secondary malignancy is
a devastating complication that contributes to the morbidity
and mortality after HSCT.
▸ We present the ﬁrst case of folliculotropic mycosis fungoides
(stage IVA2) following HSCT to derive from an unrelated
donor. A positive response to brentuximab is reported.
▸ We describe an evolving pathology with a multifactorial
aetiology including intractable cutaneous graft versus host
disease and long-term profound immunosuppression.
▸ Diagnosis required a high index of clinical suspicion and a
cohesive multidisciplinary approach. This case highlights the
vigilance required while monitoring patients following HSCT,
and others on long-term immunosuppression for alternative
diagnoses.
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